A dual magnetic resonance imaging/fluorescent contrast agent for Cathepsin-D detection

Contrast Media and Molecular Imaging

Volumn 8, Issue 2, 2013, Pages 127-139

  Ta, Robert ^a,b   Suchy, Mojmir ^a,b   Tam, Joshua H K ^a,b   Li, Alex X ^a   Martinez Santiesteban, Francisco S ^b   Scholl, Timothy J ^a,b   Hudson, Robert H E ^b   Bartha, Robert ^a,b   Pasternak, Stephen H ^a,b  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Alzheimer's disease; Cathepsin D; Cellular imaging; Cellular uptake; Contrast agent; Dual probes; Fluorescent probe; MRI

Indexed keywords

BOVINE SERUM ALBUMIN; CATHEPSIN D; CELL PENETRATING PEPTIDE; FLUORESCENT DYE; GADOLINIUM; TETRAXETAN;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CORTEX; CELL VIABILITY; CONCENTRATION RESPONSE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; ENZYME ACTIVITY; HIPPOCAMPUS; IN VITRO STUDY; IN VIVO STUDY; MAGNETIC FIELD; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; ANIMALS; BRAIN; CATHEPSIN D; CONTRAST MEDIA; HETEROCYCLIC COMPOUNDS; MAGNETIC RESONANCE IMAGING; MICE; MICE, TRANSGENIC; MICROSCOPY, FLUORESCENCE; MOLECULAR IMAGING; ORGANOMETALLIC COMPOUNDS; PEPTIDES; SUBTRACTION TECHNIQUE;

EID: 84871655715     PISSN: 15554309     EISSN: 15554317     Source Type: Journal    
DOI: 10.1002/cmmi.1502     Document Type: Article

References (54)

1. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366(9503): 2112-2117.
2. Cummings JL. Alzheimer's disease. New Engl J Med 2004; 351(1): 56-67.
3. Feldman HH, Jacova C, Robillard A, Garcia A, Chow T, Borrie M, Schipper HM, Blair M, Kertesz A, Chertkow H. Diagnosis and treatment of dementia: 2. Diagnosis. CMAJ 2008; 178(7): 825-836.
4. Golde TE, Petrucelli L, Lewis J. Targeting Abeta and tau in Alzheimer's disease, an early interim report. Exp Neurol 2010; 223(2): 252-266.
5. Benes P, Vetvicka V, Fusek M. Cathepsin D - many functions of one aspartic protease. Crit Rev Oncol Hematol 2008; 68(1): 12-28.
6. Zaidi N, Maurer A, Nieke S, Kalbacher H. Cathepsin D: a cellular roadmap. Biochem Biophys Res Commun 2008; 376(1): 5-9.
7. Cataldo AM, Hamilton DJ, Nixon RA. Lysosomal abnormalities in degenerating neurons link neuronal compromise to senile plaque development in Alzheimer disease. Brain Res 1994; 640(1-2): 68-80.
8. Cataldo AM, Hamilton DJ, Barnett JL, Paskevich PA, Nixon RA. Properties of the endosomal-lysosomal system in the human central nervous system: disturbances mark most neurons in populations at risk to degenerate in Alzheimer's disease. J Neurosci 1996; 16(1): 186-199.
9. Cataldo AM, Nixon RA. Enzymatically active lysosomal proteases are associated with amyloid deposits in Alzheimer brain. Proc Natl Acad Sci USA 1990; 87(10): 3861-3865.
10. Cataldo AM, Paskevich PA, Kominami E, Nixon RA. Lysosomal hydrolases of different classes are abnormally distributed in brains of patients with Alzheimer disease. Proc Natl Acad Sci USA 1991; 88(24): 10998-11002.
11. Nixon RA, Cataldo AM, Mathews PM. The endosomal-lysosomal system of neurons in Alzheimer's disease pathogenesis: a review. Neurochem Res 2000; 25(9-10): 1161-1172.
12. Schwagerl AL, Mohan PS, Cataldo AM, Vonsattel JP, Kowall NW, Nixon RA. Elevated levels of the endosomal-lysosomal proteinase cathepsin D in cerebrospinal fluid in Alzheimer disease. J Neurochem 1995; 64(1): 443-446.
13. Bagnoli S, Nacmias B, Tedde A, Guarnieri BM, Cellini E, Ciantelli M, Petruzzi C, Bartoli A, Ortenzi L, Serio A, Sorbi S. Cathepsin D polymorphism in Italian sporadic and familial Alzheimer's disease. Neurosci Lett 2002; 328(3): 273-276.
14. Cataldo AM, Peterhoff CM, Schmidt SD, Terio NB, Duff K, Beard M, Mathews PM, Nixon RA. Presenilin mutations in familial Alzheimer disease and transgenic mouse models accelerate neuronal lysosomal pathology. J Neuropathol Exp Neurol 2004; 63(8): 821-830.
15. Howlett DR, Bowler K, Soden PE, Riddell D, Davis JB, Richardson JC, Burbidge SA, Gonzalez MI, Irving EA, Lawman A, Miglio G, Dawson EL, Howlett ER, Hussain I. Abeta deposition and related pathology in an APP×PS1 transgenic mouse model of Alzheimer's disease. Histol Histopathol 2008; 23(1): 67-76.
16. Wirths O, Breyhan H, Marcello A, Cotel MC, Bruck W, Bayer TA. Inflammatory changes are tightly associated with neurodegeneration in the brain and spinal cord of the APP/PS1KI mouse model of Alzheimer's disease. Neurobiol Aging 2010; 31(5): 747-757.
17. Rosen Y, Lenkinski RE. Recent advances in magnetic resonance neurospectroscopy. Neurotherapeutics 2007; 4(3): 330-345.
18. Vemuri P, Jack CR, Jr. Role of structural MRI in Alzheimer's disease. Alzheimers Res Ther 2010; 2(4): 23.
19. Sperling RA, Dickerson BC, Pihlajamaki M, Vannini P, LaViolette PS, Vitolo OV, Hedden T, Becker JA, Rentz DM, Selkoe DJ, Johnson KA. Functional alterations in memory networks in early Alzheimer's disease. Neuromolecular Med 2010; 12(1): 27-43.
20. Suchy M, Ta R, Li AX, Wojciechowski F, Pasternak SH, Bartha R, Hudson RH. A paramagnetic chemical exchange-based MRI probe metabolized by cathepsin D: design, synthesis and cellular uptake studies. Org Biomol Chem 2010; 8(11): 2560-2566.
21. Viswanathan S, Kovacs Z, Green KN, Ratnakar SJ, Sherry AD. Alternatives to gadolinium-based metal chelates for magnetic resonance imaging. Chem Rev 2010; 110(5): 2960-3018.
22. Sherry AD, Woods M. Chemical exchange saturation transfer contrast agents for magnetic resonance imaging. Annu Rev Biomed Eng 2008; 10: 391-411.
23. Baechle D, Cansier A, Fischer R, Brandenburg J, Burster T, Driessen C, Kalbacher H. Biotinylated fluorescent peptide substrates for the sensitive and specific determination of cathepsin D activity. J Pept Sci 2005; 11(3): 166-174.
24. Wender PA, Mitchell DJ, Pattabiraman K, Pelkey ET, Steinman L, Rothbard JB. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc Natl Acad Sci USA 2000; 97(24): 13003-13008.
25. Vinogradov E, He H, Lubag A, Balschi JA, Sherry AD, Lenkinski RE. MRI detection of paramagnetic chemical exchange effects in mice kidneys in vivo. Magn Reson Med 2007; 58(4): 650-655.
26. Le WD, Xie WJ, Kong R, Appel SH. Beta-amyloid-induced neurotoxiity of a hybrid septal cell line associated with increased tau phosphoylation and expression of beta-amyloid precuror protein. J Neurochem 1997; 69(3): 978-985.
27. Jankowsky JL, Slunt HH, Ratovitski T, Jenkins NA, Copeland NG, Borchelt DR. Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Eng 2001; 17(6): 157-165.
28. Reiserer RS, Harrison FE, Syverud DC, McDonald MP. Impaired spatial learning in the APPSwe+PSEN1DeltaE9 bigenic mouse model of Alzheimer's disease. Genes Brain Behav 2007; 6(1): 54-65.
29. D'Andrea MR, Reiser PA, Polkovitch DA, Gumula NA, Branchide B, Hertzog BM, Schmidheiser D, Belkowski S, Gastard MC, Andrade-Gordon P. The use of formic acid to embellish amyloid plaque detection in Alzheimer's disease tissues misguides key observations. Neurosci Lett 2003; 342(1-2): 114-118.
30. Caravan P, Farrar CT, Frullano L, Uppal R. Influence of molecular parameters and increasing magnetic field strength on relaxivity of gadolinium- and manganese-based T1 contrast agents. Contrast Media Mol Imag 2009; 4(2): 89-100.
31. Nieminen MT, Rieppo J, Silvennoinen J, Toyras J, Hakumaki JM, Hyttinen MM, Helminen HJ, Jurvelin JS. Spatial assessment of articular cartilage proteoglycans with Gd-DTPA-enhanced T1 imaging. Magn Reson Med 2002; 48(4): 640-648.
32. Endres PJ, MacRenaris KW, Vogt S, Meade TJ. Cell-permeable MR contrast agents with increased intracellular retention. Bioconjugate Chem 2008; 19(10): 2049-2059.
33. Korb JP, Diakova G, Goddard Y, Bryant RG. Relaxation of protons by radicals in rotationally immobilized proteins. J Magn Reson Imag 2007; 186(2): 176-181.
34. Lopiano L, Fasano M, Giraudo S, Digilio G, Koenig SH, Torre E, Bergamasco B, Aime S. Nuclear magnetic relaxation dispersion profiles of substantia nigra pars compacta in Parkinson's disease patients are consistent with protein aggregation. Neurochem Int 2000; 37: 331-336.
35. Laurent S, Elst LV, Muller RN. Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. Contrast Media Mol Imag 2006; 1(3): 128-137.
36. Strijkers GJ, Mulder WJM, van Heeswijk RB, Frederik PM, Bomans P, Magusin PCMM, Nicolay K. Relaxivity of liposomal paramagnetic MRI contrast agents. MAGMA 2005; 18: 186-192.
37. Aime S, Delli Castelli D, Geninatti Crich S, Gianolio E, Terreno E. Pushing the sensitivity envelope of lanthanide-based magnetic resonance imaging (MRI) contrast agents for molecular imaging applications. Acc Chem Res 2009; 42(7): 822-831.
38. Bernstein HG, Wiederanders B. An immunohistochemical study of cathepsin E in Alzheimer-type dementia brains. Brain Res 1994; 667: 287-290.
39. Aime S, Cabella C, Colombatto S, Geninatti CS, Gianolio E, Maggioni F. Insights into the use of paramagnetic Gd(III) complexes in MR-molecular imaging investigations. J Magn Reson Imag 2002; 16(4): 394-406.
40. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang GF, Estrada S, Ausen B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Langstrom B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55(3):306-319.
41. Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, Pontecorvo MJ, Hefti F, Carpenter AP, Flitter ML, Krautkramer MJ, Kung HF, Coleman RE, Doraiswamy PM, Fleisher AS, Sabbagh MN, Sadowsky CH, Reiman EP, Zehntner SP, Skovronsky DM. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 2011; 305(3): 275-283.
42. Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, Hiemeyer F, Wittemer-Rump SM, Seibyl J, Reininger C, Sabri O. Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol 2011; 10(5): 424-435.
43. Jack CR, Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, Shiung MM, Gunter JL, Boeve BF, Kemp BJ, Weiner M, Petersen RC. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009; 132(Pt 5): 1355-1365.
44. Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X, Meltzer CC, Schimmel K, Tsopelas ND, DeKosky ST, Price JC. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med 2005; 46(12): 1959-1972.
45. Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, Miller BL, Koeppe RA, Mathis CA, Weiner MW, Jagust WJ. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 2009; 132(Pt 5): 1310-1323.
46. Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 2000; 283(12): 1571-1577.
47. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 1999; 155(3): 853-862.
48. Walsh DM, Selkoe DJ. A beta oligomers - a decade of discovery. J Neurochem 2007; 101(5): 1172-1184.
49. Ropele S, Seifert T, Enzinger C, Fazekas F. Method for quantitative imaging of the macromolecular 1H fraction in tissues. Magn Reson Med 2003; 49(5): 864-871.
50. Hammond DN, Lee HJ, Tonsgard JH, Wainer BH. Development and characterization of clonal cell lines derived from septal cholinergic neurons. Brain Res 1990; 512(2): 190-200.
51. Barbosa J, Jr, Massensini AR, Santos MS, Meireles SI, Gomez RS, Gomez MV, Romano-Silva MA, Prado VF, Prado MA. Expression of the vesicular acetylcholine transporter, proteins involved in exocytosis, and functional calcium signaling in varicosities and soma of a murine septal cell line. J Neurochem 1999; 73(5): 1881-1893.
52. Kushmerick C, Romano-Silva MA, Gomez MV, Prado MA. Changes in Ca(2+) channel expression upon differentiation of SN56 cholinergic cells. Brain Res 2001; 916(1-2): 199-210.
53. Blusztajn JK, Venturini A, Jackson DA, Lee HJ, Wainer BH. Acetylcholine synthesis and release is enhanced by dibutyryl cyclic AMP in a neuronal cell line derived from mouse septum. J Neurosci 1992; 12(3): 793-799.
54. Lorenzen A, Samosh J, Vandewark K, Anborgh PH, Seah C, Magalhaes AC, Cregan SP, Ferguson SS, Pasternak SH. Rapid and direct transport of cell surface APP to the lysosome defines a novel selective pathway. Mol Brain 2010; 3: 11.